Bardzo tanie apteki z dostawą w całej Polsce kupic viagra i ogromny wybór pigułek.

Pii: s0272-6386(03)00125-2

REFERENCES
1. Collins AJ, Roberts TL, St Peter WL, Chen SC, Ebben lar risk factor in end-stage renal disease. Circulation 97:138- J, Constantini E: United States Renal Data System assess- ment of the impact of the National Kidney Foundation- 14. Kunz K, Petitjean P, Lisri M, et al: Cardiovascular Dialysis Outcomes Quality Initiative guidelines. Am J Kid- morbidity and endothelial dysfunction in chronic haemodi- alysis patients: Is homocyst(e)ine the missing link? Nephrol 2. National Kidney Foundation: K/DOQI clinical prac- tice guidelines for chronic kidney disease: Evaluation, clas- 15. Ducloux D, Motte G, Challier B, Gibey R, Chalopin sification, and stratification. Am J Kidney Dis 39:S1-S266, JM: Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: A 3. Expert Panel on Detection Evaluation and Treatment prospective study. J Am Soc Nephrol 11:134-137, 2000 of High Blood Cholesterol in Adults: Executive Summary of 16. Mallamaci F, Zoccali C, Tripepi G, et al: Hyperhomo- the Third Report of the National Cholesterol Education cysteinemia predicts cardiovascular oucomes in hemodialy- Program (NCEP) Expert Panel on Detection, Evaluation, sis patients. Kidney Int 61:609-614, 2002 17. Stenvinkel P, Heimburger O, Paultre F, et al: Strong and Treatment of High Blood Cholesterol in Adults (Adult association between malnutrition, inflammation, and athero- Treatment Panel III). JAMA 285:2486-2497, 2001 sclerosis in chronic renal failure. Kidney Int 55:1899-1911, 4. Levey AS, Beto JA, Coronado BE, et al: Controlling the epidemic of cardiovascular disease in chronic renal 18. Zimmermann J, Herrlinger S, Pruy A, Metzger T, disease: What do we know? What do we need to learn? Wanner C: Inflammation enhances cardiovascular risk and Where do we go from here? National Kidney Foundation mortality in hemodialysis patients. Kidney Int 55:648-658, Task Force on Cardiovascular Disease. Am J Kidney Dis 19. Stenvinkel P, Lindholm B, Heimburger M, Heim- 5. United States Renal Data System: USRDS 2000 An- burger O: Elevated serum levels of soluble adhesion mol- nual Data Report: Atlas of End-Stage Renal Diseas in the ecules predict death in pre-dialysis patients: Association United States (ed 12th Annual Report). Bethesda, MD, with malnutrition, inflammation, and cardiovascular disease.
Division of Kidney, Urologic, and Hematological Diseases, Nephrol Dial Transplant 15:1624-1630, 2000 National Institute of Diabetes and Digestive Kidney Dis- 20. Yeun JY, Levine RA, Mantadilok V, Kaysen GA: eases, National Institutes of Health, 2000 C-reactive protein predicts all-cause and cardiovascular mor- 6. National Cholesterol Education Program: Report of tality in hemodialysis patients. Am J Kidney Dis 35:469- the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 89:525-584, 1992 21. Haubitz M, Brunkhorst R: C-reactive protein and 7. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: chronic Chlamydia pneumoniae infection—Long-term pre- Association of serum phosphorus and calcium x phosphate dictors for cardiovascular disease and survival in patients on product with mortality risk in chronic hemodialysis patients: peritoneal dialysis. Nephrol Dial Transplant 16:809-815, A national study. Am J Kidney Dis 31:607-617, 1998 8. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, 22. Jungers P, Massy ZA, Nguyen Khoa T, et al: Inci- Port FK: Association of elevated serum PO(4), Ca x PO(4) dence and risk factors of atherosclerotic cardiovascular product, and parathyroid hormone with cardiac mortality accidents in predialysis chronic renal failure patients: A risk in chronic hemodialysis patients. J Am Soc Nephrol prospective study. Nephrol Dial Transplant 12:2597-2602, 9. Massy ZA, Chadefaux-Vekemans B, Chevalier A, et 23. Landray MJ, Thambyrajah J, McGlynn FJ, et al: al: Hyperhomocysteinaemia: A significant risk factor for Epidemiological evaluation of known and suspected cardio- cardiovascular disease in renal transplant recipients. Neph- vascular risk factors in chronic renal impairment. Am J 10. Bostom AG, Shemin D, Lapane KL, et al: Hyperho- 24. Tonelli M, Bohm C, Pandeya S, Gill J, Levin A, mocysteinemia and traditional cardiovascular disease risk Kiberd BA: Cardiac risk factors and the use of cardioprotec- factors in end-stage renal disease patients on dialysis: A tive medications in patients with chronic renal insufficiency.
Am J Kidney Dis 37:484-489, 2001 case-control study. Atherosclerosis 114:93-103, 1995 25. Levin A, Djurdjev O, Barrett B, et al: Cardiovascular 11. Bostom AG, Shemin D, Verhoef P, et al: Elevated disease in patients with chronic kidney disease: Getting to fasting total plasma homocysteine levels and cardiovascular the heart of the matter. Am J Kidney Dis 38:1398-1407, disease outcomes in maintenance dialysis patients. A prospec- tive study. Arterioscler Thromb Vasc Biol 17:2554-2558, 26. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high 12. Jungers P, Chauveau P, Bandin O, et al: Hyperhomo- blood pressure. Arch Intern Med 157:2413-2446, 1997 cysteinemia is associated with atherosclerotic occlusive arte- 27. The Expert Committee on the Diagnosis and Classifi- rial accidents in predialysis chronic renal failure patients.
Miner Electrolyte Metab 23:170-173, 1997 13. Moustapha A, Naso A, Nahlawi M, et al: Prospective 2003 by the National Kidney Foundation, Inc. study of hyperhomocysteinemia as an adverse cardiovascu- American Journal of Kidney Diseases, Vol 41, No 4, Suppl 3 (April), 2003: pp S77-S91 cation of Diabetes Mellitus: American Diabetes Association 43. Holdaas H, Fellstro¨m B, Holme I, et al: Effects of clinical practice recommendations 2002. Diabetes Care 25: fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol௡in Renal Transplantation) 28. Mosca L, Collins P, Herrington DM, et al: Hormone study design and baseline data. J Cardiovasc Risk 8:63-71, replacement therapy and cardiovascular disease: A statement for healthcare professionals from the American Heart Asso- 44. Wanner C, Krane V, Ruf G, Marz W, Ritz E: Ratio- nale and design of a trial improving outcome of type 2 29. US Preventive Services Task Force: Aspirin for the diabetics on hemodialysis. Die Deutsche Diabetes Dialyse primary prevention of cardiovascular events: Recommenda- Studie Investigators. Kidney Int Suppl 71:S222-S226, 1999 tion and rationale. Ann Intern Med 136:157-160, 2002 45. Diercks GF, Janssen WM, van Boven AJ, et al: 30. Krauss RM, Eckel RH, Howard B, et al: AHA Dietary Rationale, design, and baseline characteristics of a trial of Guidelines: Revision 2000: A satement for healthcare profes- prevention of cardiovascular and renal disease with fosino- sionals from the Nutrition Committee of the American Heart pril and pravastatin in nonhypertensive, nonhypercholester- Association. Circulation 102:2284-2299, 2000 olemic subjects with microalbuminuria (the Prevention of 31. Smith SC Jr, Blair SN, Bonow RO, et al: AHA/ACC REnal and Vascular ENdstage Disease Intervention Trial Scientific Statement: AHA/ACC guidelines for preventing [PREVEND IT]). Am J Cardiol 86:635-638, 2000 heart attack and death in patients with atherosclerotic cardio- 46. LaRosa JC, He J, Vupputuri S: Effect of statins on vascular disease: 2001 update: A statement for healthcare risk of coronary disease: A meta-analysis of randomized professionals from the American Heart Association and the controlled trials. JAMA 282:2340-2346, 1999 American College of Cardiology. Circulation 104:1577- 47. Sacks FM, Tonkin AM, Shepherd J, et al: Effect of pravastatin on coronary disease events in subgroups defined 32. Goldstein LB, Adams R, Becker K, et al: Primary by coronary risk factors: The Prospective Pravastatin Pool- prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart 48. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Association. Circulation 103:163-182, 2001 Olsson AG, Thorgeirsson G: Cholesterol lowering with 33. A clinical practice guideline for treating tobacco use simvastatin improves prognosis of diabetic patients with and dependence: A US Public Health Service report. The coronary heart disease. A subgroup analysis of the Scandina- Tobacco Use and Dependence Clinical Practice Guideline vian Simvastatin Survival Study (4S). Diabetes Care 20:614- Panel, Staff, and Consortium Representatives. JAMA 283: 49. The Long-term Intervention with Pravastatin in Isch- 34. MRC/BHF Heart Protection Study of cholesterol low- aemic Disease (LIPID) Study Group: Prevention of cardio- ering with simvastatin in 20,536 high-risk individuals: A vascular events and death with pravastatin in patients with randomised placebo-controlled trial. Lancet 360:7-22, 2002 coronary heart disease and a broad range of initial choles- 35. Davis BR, Cutler JA, Gordon DJ, et al: Rationale and terol levels. The Long-Term Intervention with Pravastatin in design for the Antihypertensive and Lipid Lowering Treat- Ischaemic Disease (LIPID) Study Group. N Engl J Med ment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens 9:342-360, 1996 50. Goldberg RB, Mellies MJ, Sacks FM, et al: Cardiovas- 36. MacMahon M, Kirkpatrick C, Cummings CE, et al: A cular events and their reduction with pravastatin in diabetic pilot study with simvastatin and folic acid/vitamin B12 in and glucose-intolerant myocardial infarction survivors with preparation for the Study of the Effectiveness of Additional average cholesterol levels: Subgroup analyses in the choles- Reductions in Cholesterol and Homocysteine (SEARCH).
terol and recurrent events (CARE) trial. The Care Investiga- Nutr Metabol Cardiovasc Dis 10:195-203, 2000 37. Brown WV: Cholesterol lowering in atherosclerosis.
51. Schwartz GG, Olsson AG, Ezekowitz MD, et al: Effects of atorvastatin on early recurrent ischemic events in 38. Gotto AM: Ongoing clinical trials of statins. Am J acute coronary syndromes: The MIRACL study: A random- ized controlled trial. JAMA 285:1711-1718, 2001 39. Isaacsohn JL, Davidson MH, Hunninghake D, Singer 52. Goldbourt U, Behar S, Reicher-Reiss H, et al: Ratio- R, McLain R, Black DM: Aggressive Lipid-Lowering Initia- nale and design of a secondary prevention trial of increasing tive Abates New Cardiac Events (ALLIANCE)-rationale serum high-density lipoprotein cholesterol and reducing and design of atorvastatin versus usual care in hypercholes- triglycerides in patients with clinically manifest atheroscle- terolemic patients with coronary artery disease. Am J Car- rotic heart disease (the Bezafibrate Infarction Prevention 40. Cannon CP, McCabe CH, Belder R, Breen J, Braun- 53. Secondary prevention by raising HDL cholesterol wald E: Design of the Pravastatin or Atorvastatin Evaluation and reducing triglycerides in patients with coronary artery and Infection Therapy (PROVE IT)-TIMI 22 trial. Am J disease: The Bezafibrate Infarction Prevention (BIP) study.
41. Shepherd J, Blauw GJ, Murphy MB, et al: The design 54. McCormick LS, Black DM, Waters D, Brown WV, of a prospective study of Pravastatin in the Elderly at Risk Pitt B: Rationale, design, and baseline characteristics of a (PROSPER). Am J Cardiol 84:1192-1197, 1999 trial comparing aggressive lipid lowering with Atorvastatin 42. Steiner G: Lipid intervention trials in diabetes. Diabe- Versus Revascularization Treatments (AVERT). Am J Car- 55. Design features and baseline characteristics of the patients with coronary heart disease: The Scandinavian LIPID (Long-Term Intervention with Pravastatin in Isch- Simvastatin Survival Study (4S). Lancet 344:1383-1389, emic Disease) Study: A randomized trial in patients with previous acute myocardial infarction and/or unstable angina 68. Waters D, Higginson L, Gladstone P, et al: Effects of monotherapy with an HMG-CoA reductase inhibitor on the 56. The Long-Term Intervention with Pravastatin in Isch- progression of coronary atherosclerosis as assessed by serial aemic Disease (LIPID) Study Group: Prevention of cardio- quantitative arteriography. The Canadian Coronary Athero- vascular events and death with pravastatin in patients with sclerosis Intervention Trial. Circulation 89:959-968, 1994 coronary heart disease and a broad range of initial choles- 69. Bradford RH, Shear CL, Chremos AN, et al: Ex- terol levels. The Long-Term Intervention with Pravastatin in panded clinical evaluation of lovastatin (EXCEL) study: Ischaemic Disease (LIPID) Study Group. N Engl J Med Design and patient characteristics of a double-blind, placebo- controlled study in patients with moderate hypercholesterol- 57. Downs JR, Beere PA, Whitney E, et al: Design & rationale of the Air Force/Texas Coronary Atherosclerosis 70. Bradford RH, Shear CL, Chremos AN, et al: Ex- Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 80: panded Clinical Evaluation of Lovastatin (EXCEL) study results: Two-year efficacy and safety follow-up. Am J Car- 58. Downs JR, Clearfield M, Weis S, et al: Primary prevention of acute coronary events with lovastatin in men 71. Ma¨ntta¨ri M, Elo O, Frick MH, et al: The Helsinki and women with average cholesterol levels: Results of Heart Study: Basic design and randomization procedure. Eur AFCAPS/TexCAPS. Air Force/Texas Coronary Atheroscle- rosis Prevention Study. JAMA 279:1615-1622, 1998 72. Frick MH, Elo O, Haapa K, et al: Helsinki heart 59. Sacks FM, Pfeffer MA, Moye´ L, et al: Rationale and study: Primary-prevention trial with gemfibrozil in middle- design of a secondary prevention trial of lowering normal aged men with dyslipidemia. N Engl J Med 317:1237-1245, plasma cholesterol levels after acute myocardial infarction: The Cholesterol and Recurrent Events trial (CARE). Am J 73. Ma¨ntta¨ri M, Tiula E, Alikoski T, Manninen V: Effects of hypertension and dyslipidemia on the decline in renal 60. Sacks FM, Pfeffer MA, Moye LA, et al: The effect of pravastatin on coronary events after myocardial infarction in 74. Brown G, Albers JJ, Fisher LD, et al: Regression of patients with average cholesterol levels. Cholesterol and coronary artery disease as a result of intensive lipid- Recurrent Events Trial investigators. N Engl J Med 335:1001- lowering therapy in men with high levels of apolipoprotein 61. West MS, Herd JA, Ballantyne CM, et al: The Li- 75. Rubins HB, Robins SJ, Iwane MK, et al: Rationale poprotein and Coronary Atherosclerosis Study (LCAS): De- and design of the Department of Veterans Affairs High- sign, methods, and baseline data of a trial of fluvastatin in Density Lipoprotein Cholesterol Intervention Trial (HIT) for patients without severe hypercholesterolemia. Control Clin secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low- 62. The West of Scotland Coronary Prevention Study density lipoprotein cholesterol. Am J Cardiol 71:45-52, Group: A coronary primary prevention study of Scottish men aged 45-64 years: Trial design. The West of Scotland Coro- 76. Blankenhorn DH, Azen SP, Kramsch DM, et al: nary Prevention Study Group. J Clin Epidemiol 45:849-860, Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). The 63. Shepherd J, Cobbe SM, Ford I, et al: Prevention of MARS Research Group. Ann Intern Med 119:969-976, 1993 coronary heart disease with pravastatin in men with hyper- 77. Effect of simvastatin on coronary atheroma: The cholesterolemia. West of Scotland Coronary Prevention Study Multicentre Anti-Atheroma Study (MAAS). Lancet 344:633- 64. Jukema JW, Bruschke AV, van Boven AJ, et al: 78. Haskell WL, Alderman EL, Fair JM, et al: Effects of Effects of lipid lowering by pravastatin on progression and intensive multiple risk factor reduction on coronary athero- regression of coronary artery disease in symptomatic men sclerosis and clinical cardiac events in men and women with with normal to moderately elevated serum cholesterol lev- coronary artery disease. The Stanford Coronary Risk Inter- els. The Regression Growth Evaluation Statin Study (RE- vention Project (SCRIP). Circulation 89:975-990, 1994 79. The effect of aggressive lowering of low-density 65. Pitt B, Mancini GB, Ellis SG, Rosman HS, Park JS, lipoprotein cholesterol levels and low-dose anticoagulation McGovern ME: Pravastatin limitation of atherosclerosis in on obstructive changes in saphenous-vein coronary-artery the coronary arteries (PLAC I): Reduction in atherosclerosis bypass grafts. The Post Coronary Artery Bypass Graft Trial progression and clinical events PLAC I investigation. J Am Investigators. N Engl J Med 336:153-162, 1997 80. Bestehorn HP, Rensing UF, Roskamm H, et al: The 66. Design and baseline results of the Scandinavian Sim- effect of simvastatin on progression of coronary artery vastatin Survival Study of patients with stable angina and/or disease. The Multicenter coronary Intervention Study (CIS).
previous myocardial infarction. Am J Cardiol 71:393-400, 81. Frick MH, Syvanne M, Nieminen MS, et al: Preven- 67. Randomised trial of cholesterol lowering in 4444 tion of the angiographic progression of coronary and vein- graft atherosclerosis by gemfibrozil after coronary bypass risk factors in survival of hemodialyzed patients. Am J surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circu- 98. Fujisawa M, Haramaki R, Miyazaki H, Imaizumi T, Okuda S: Role of lipoprotein (a) and TGF-beta 1 in athero- 82. Effect of fenofibrate on progression of coronary- sclerosis of hemodialysis patients. J Am Soc Nephrol 11: artery disease in type 2 diabetes: The Diabetes Atherosclero- sis Intervention Study, a randomised study. Lancet 357:905- 99. Webb AT, Brown EA: Prevalence of symptomatic arterial disease and risk factors for its development in 83. Albert MA, Staggers J, Chew P, Ridker PM: The patients on continuous ambulatory peritoneal dialysis. Perit pravastatin inflammation CRP evaluation (PRINCE): Ratio- nale and design. Am Heart J 141:893-898, 2001 100. Milionis HJ, Elisaf MS, Tselepis A, Bairaktari E, 84. Seliger SL, Weiss NS, Gillen DL, et al: HMG-CoA Karabina SA, Siamopoulos KC: Apolipoprotein(a) pheno- reductase inhibitors are associated with reduced mortality in types and lipoprotein(a) concentrations in patients with renal ESRD patients. Kidney Int 61:297-304, 2002 failure. Am J Kidney Dis 33:1100-1106, 1999 85. Lowrie EG, Lew NL: Death risk in hemodialysis 101. Kimak E, Solski J, Janicka L, Ksaziek A, Janicki K: patients: The predictive value of commonly measured vari- Concentration of Lp(a) and other apolipoproteins in predialy- ables and an evaluation of death rate differences between sis, hemodialysis, chronic ambulatory peritoneal dialysis facilities. Am J Kidney Dis 15:458-482, 1990 and post-transplant patients. Clin Chem Lab Med 38:421- 86. Lowrie EG, Lew NL: Commonly measured labora- tory variables in hemodialysis patients: Relationships among 102. Maggi E, Bellazzi R, Falaschi F, et al: Enhanced them and to death risk. Semin Nephrol 12:276-283, 1992 LDL oxidation in uremic patients: An additional mechanism 87. Iseki K, Yamazato M, Tozawa M, Takishita S: Hypo- for accelerated atherosclerosis? Kidney Int 45:876-883, 1994 cholesterolemia is a significant predictor of death in a cohort 103. Maggi E, Bellazzi R, Gazo A, Seccia M, Bellomo G: of chronic hemodialysis patients. Kidney Int 61:1887-1893, Autoantibodies against oxidatively-modified LDL in uremic patients undergoing dialysis. Kidney Int 46:869-876, 1994 88. Bologa RM, Levine DM, Parker TS, et al: Interleu- 104. Koniger M, Quaschning T, Wanner C, Schollmeyer kin-6 predicts hypoalbuminemia, hypocholesterolemia, and P, Kramer-Guth A: Abnormalities in lipoprotein metabolism mortality in hemodialysis patients. Am J Kidney Dis 32:107- in hemodialysis patients. Kidney Int Suppl 71:S248-S250, 89. Cheung AK, Sarnak MJ, Yan G, et al: Atherosclerotic 105. Ziouzenkova O, Asatryan L, Akmal M, et al: Oxida- cardiovascular disease risks in chronic hemodialysis pa- tive cross-linking of ApoB100 and hemoglobin results in low density lipoprotein modification in blood. Relevance to 90. Kronenberg F, Neyer U, Lhotta K, et al: The low atherogenesis caused by hemodialysis. J Biol Chem 274: molecular weight apo(a) phenotype is an independent predic- tor for coronary artery disease in hemodialysis patients: A 106. O’Byrne D, Devaraj S, Islam KN, et al: Low-density prospective follow-up. J Am Soc Nephrol 10:1027-1036, lipoprotein (LDL)-induced monocyte-endothelial cell adhe- sion, soluble cell adhesion molecules, and autoantibodies to 91. Cressman MD, Heyka RJ, Paganini EP, O’Neil J, Skibinski CI, Hoff HF: Lipoprotein(a) is an independent risk oxidized-LDL in chronic renal failure patients on dialysis factor for cardiovascular disease in hemodialysis patients.
107. Boaz M, Smetana S, Weinstein T, et al: Secondary 92. Stack AG, Bloembergen WE: Prevalence and clinical prevention with antioxidants of cardiovascular disease in correlates of coronary artery disease among new dialysis endstage renal disease (SPACE): Randomised placebo- patients in the United States: A cross-sectional study. J Am controlled trial. Lancet 356:1213-1218, 2000 108. Stephens NG, Parsons A, Schofield PM, Kelly F, 93. Koda Y, Nishi S, Suzuki M, Hirasawa Y: Lipopro- Cheeseman K, Mitchinson MJ: Randomised controlled trial tein(a) is a predictor for cardiovascular mortality of hemodi- of vitamin E in patients with coronary disease: Cambridge alysis patients. Kidney Int Suppl 71:S251-S253, 1999 Heart Antioxidant Study (CHAOS). Lancet 347:781-786, 94. Degoulet P, Legrain M, Re¨ach I, et al: Mortality risk factors in patients treated by chronic hemodialysis. Report 109. Rapola JM, Virtamo J, Ripatti S, et al: Randomised of the Diaphane collaborative study. Nephron 31:103-110, trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous 95. Iseki K, Uehara H, Nishime K, et al: Impact of the myocardial infraction. Lancet 349:1715-1720, 1997 initial levels of laboratory variables on survival in chronic 110. Gruppo Italiano per lo Studio della Sopravvivenza dialysis patients. Am J Kidney Dis 28:541-548, 1996 nell’Infarto miocardico: Dietary supplementation with n-3 96. Goldwasser P, Michel MA, Collier J, et al: Prealbu- polyunsaturated fatty acids and vitamin E after myocardial min and lipoprotein(a) in hemodialysis: Relationships with infarction: Results of the GISSI-Prevenzione trial. Gruppo patient and vascular access survival. Am J Kidney Dis Italiano per lo Studio della Sopravvivenza nell’Infarto mio- 97. Kimura G, Tomita J, Nakamura S, Uzu T, Inenaga T: 111. Leppala JM, Virtamo J, Fogelholm R, et al: Con- Interaction between hypertension and other cardiovascular trolled trial of alpha-tocopherol and beta-carotene supple- ments on stroke incidence and mortality in male smokers.
Wanner C, Kramer-Guth A: Immunosuppression enhances Arterioscler Thromb Vasc Biol 20:230-235, 2000 atherogenicity of lipid profile after transplantation. Kidney 112. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P: Vitamin E supplementation and cardiovascular events in 128. Kasiske BL, Guijarro C, Massy ZA, Wiederkehr high-risk patients. The Heart Outcomes Prevention Evalua- MR, Ma JZ: Cardiovascular disease after renal transplanta- tion Study Investigators. N Engl J Med 342:154-160, 2000 113. Collaborative Group of the Primary Prevention 129. Aker S, Ivens K, Grabensee B, Heering P: Cardiovas- Project: Low-dose aspirin and vitamin E in people at cardio- cular risk factors and diseases after renal transplantation. Int vascular risk. A randomised trial in general practice. Collabo- rative Group of the Primary Prevention Project. Lancet 130. Aakhus S, Dahl K, Widerøe TE: Cardiovascular morbidity and risk factors in renal transplant patients. Neph- 114. Brown BG, Zhao XQ, Chait A, et al: Simvastatin and niacin, antioxidant vitamins, or the combination for the 131. Kasiske BL, Chakkera H, Roel J: Explained and prevention of coronary disease. N Engl J Med 345:1583- unexplained ischemic heart disease risk after renal transplan- tation. J Am Soc Nephrol 11:1735-1743, 2000 115. Collins R, Peto R, Armitage J: The MRC/BHF Heart 132. Ong CS, Pollock CA, Caterson RJ, Mahony JF, Protection Study: Preliminary results. Int J Clin Pract 56:53- Waugh DA, Ibels LS: Hyperlipidemia in renal transplant recipients: Natural history and response to treatment. Medi- 116. Nestel PJ, Fidge NH, Tan MH: Increased lipoprotein- remnant formation in chronic renal failure. N Engl J Med 133. Barbagallo CM, Pinto A, Gallo S, et al: Carotid atherosclerosis in renal transplant recipients: Relationships 117. Ron D, Oren I, Aviram M, Better OS, Brook JG: with cardiovascular risk factors and plasma lipoproteins.
Accumulation of lipoprotein remnants in patients with chronic renal failure. Atherosclerosis 46:67-75, 1983 134. Roodnat JI, Mulder PG, Zietse R, et al: Cholesterol 118. Senti M, Romero R, Pedro-Botet J, Pelegri A, Nogues as an independent predictor of outcome after renal transplan- X, Rubies-Prat J: Lipoprotein abnormalities in hyperlipid- tation. Transplantation 69:1704-1710, 2000 emic and normolipidemic men on hemodialysis with chronic 135. Massy ZA, Mamzer-Bruneel MF, Chevalier A, et al: renal failure. Kidney Int 41:1394-1399, 1992 Carotid atherosclerosis in renal transplant recipients. Neph- 119. Cheung AK, Wu LL, Kablitz C, Leypoldt JK: Athero- genic lipids and lipoproteins in hemodialysis patients. Am J 136. Biesenbach G, Margreiter R, Konigsrainer A, et al: Comparison of progression of macrovascular diseases after 120. Shoji T, Nishizawa Y, Kawagishi T, et al: Intermedi- kidney or pancreas and kidney transplantation in diabetic ate-density lipoprotein as an independent risk factor for patients with end-stage renal disease. Diabetologia 43:231- aortic atherosclerosis in hemodialysis patients. J Am Soc 137. Scanferla F, Toffoletto PP, Roncali D, Bazzato G: 121. Oi K, Hirano T, Sakai S, Kawaguchi Y, Hosoya T: Associated effect of hepatic hydroxymethylglutaryl coen- Role of hepatic lipase in intermediate-density lipoprotein zyme A reductase ϩ angiotensin converting enzyme inhibi- and small, dense low-density lipoprotein formation in hemo- tors on the progression of renal failure in hypertensive dialysis patients. Kidney Int Suppl 71:S227-S228, 1999 122. Hirany S, O’Byrne D, Devaraj S, Jialal I: Remnant- 138. Hommel E, Andersen P, Gall M-A, et al: Plasma like particle-cholesterol concentrations in patients with type lipoproteins and renal function during simvastatin treatment 2 diabetes mellitus and end-stage renal disease. Clin Chem in diabetic nephropathy. Diabetologia 35:447-451, 1992 139. Nielsen S, Schmitz O, Møller N, et al: Renal func- 123. Deighan CJ, Caslake MJ, McConnell M, Boulton- tion and insulin sensitivity during simvastatin treatment in Jones JM, Packard CJ: Atherogenic lipoprotein phenotype in Type 2 (non-insulin-dependent) diabetic patients with mi- end-stage renal failure: Origin and extent of small dense croalbuminuria. Diabetologia 36:1079-1086, 1993 low-density lipoprotein formation. Am J Kidney Dis 35:852- 140. Thomas ME, Harris KPG, Ramaswamy C, et al: Simvastatin therapy for hypercholesterolemic patients with 124. Olivares J, Cruz C, Gas JM, et al: Evolution of lipid nephrotic syndrome or significant proteinuria. Kidney Int profiles in long-term peritoneal dialysis. Adv Perit Dial 141. Aranda Arcas JL, Sanchez R, Guijarro C, et al: 125. Ghanem H, van den Dorpel MA, Weimar W, Man in [Effect of pravastatin on hypercholesterolemia associated ’t Veld AJ, El-kannishy MH, Jansen H: Increased low with proteinuria]. An Med Interna 11:523-527, 1994 density lipoprotein oxidation in stable kidney transplant 142. Lam KSL, Cheng IKP, Janus ED, Pang RWC: Cho- lesterol-lowering therapy may retard the progression of 126. van den Dorpel MA, Ghanem H, Rischen-Vos J, diabetic nephropathy. Diabetologia 38:604-609, 1995 Man in ’t Veld AJ, Jansen H, Weimar W: Conversion from 143. Rayner BL, Byrne MJ, van Zyl Smit R: A prospec- cyclosporine A to azathioprine treatment improves LDL tive clinical trial comparing the treatment of idiopathic oxidation in kidney transplant recipients. Kidney Int 51:1608- membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone. Clin Nephrol 46:219- 127. Quaschning T, Mainka T, Nauck M, Rump LC, 144. Smulders YM, Van Eeden AE, Stehouwer CDA, 160. Gall M-A, Nielsen FS, Smidt UM, Parving H-H: Weijers RNM, Slaats EH, Silberbusch J: Can reduction in The course of kidney function in type 2 (non-insulin- hypertriglyceridemia slow progression of microalbuminuria dependent) diabetic patients with diabetic nephropathy. Dia- in patients with non-insulin-dependent diabetes mellitus? 161. Locatelli F, Alberti D, Graziani G, Buccianti G, 145. Tonolo G, Ciccarese M, Brizzi P, et al: Reduction of Redaelli B, Giangrande: Prospective, randomised, multicen- albumin excretion rate in normotensive microalbumiuric tre trial of effect of protein restriction on progression of type 2 diabetic pateints during long-term simvastatin treat- chronic renal insufficiency. Northern Italian Cooperative 146. Olbricht CJ, Wanner C, Thiery J, Basten A, for the 162. Dillon JJ: The quantitative relationship between Simvastatin in Nephrotic Syndrome Study Group: Simvasta- treated blood pressure and progression of diabetic renal tin in nephrotic syndrome. Kidney Int Suppl 71:S113-S116, disease. Am J Kidney Dis 22:798-802, 1993 163. Biesenbach G, Janko O, Zazgornik J: Similar rate of 147. Nishimura M, Sasaki T, Oishi A, et al: Angiotensin progression in the predialysis phase in type I and type II converting enzyme inhibitor and probucol suppress time- diabetes mellitus. Nephrol Dial Transplant 9:1097-1102, dependent increase in urinary type IV collagen excretion of NIDDM with early nephropathy. J Am Soc Nephrol 10: 164. Toth T, Takebayashi S: Factors contributing to the outcome in 100 adult patients with idiopathic membranous 148. Buemi M, Allegra A, Corica F, et al: Effect of glomerulonephritis. Int Urol Nephrol 26:93-106, 1994 fluvastatin on proteinuria in patients with immunoglobulin A 165. Sentı´ M, Romero R, Pedro-Botet J, Pelegrı´ A, Nogue´s nephropathy. Clin Pharmacol Ther 67:427-431, 2000 X, Rubie´s-Prat J: Lipoprotein abnormalities in hyperlipid- 149. Fried LF, Orchard TJ, Kasiske BL: The effect of emic and normolipidemic men on hemodialysis with chronic lipid reduction on renal disease progression: A meta- renal failure. Kidney Int 41:1394-1399, 1992 166. Hernandez E, Praga M, Alamo C, et al: Lipopro- 150. Walker WG: Hypertension-related renal injury: A tein(a) and vascular access survival in patients on chronic major contributor to end-stage renal disease. Am J Kidney 167. Avram MM, Antignani A, Goldwasser P, et al: 151. Hunsicker LG, Adler S, Caggiula A, et al: Predictors Lipids in diabetic and nondiabetic hemodialysis and CAPD of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 51:1908-1919, 1997 168. Parra HJ, Cachera C, Equagoo K, Dracon M, Fru- 152. Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rach- chart JC, Tacquet A: Quantitative abnormalities of lipopro- mani R: Main risk factors for nephropathy in type 2 diabetes tein particles in chronic hemodialysis patients. Adv Exp mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 158:998-1004, 1998 169. Aakhus S, Dahl K, Widerøe TE: Hyperlipidaemia in 153. Klein R, Klein BE, Moss SE, Cruickshank KJ, renal transplant patients. J Intern Med 239:407-415, 1996 Brazy PC: The 10-year incidence of renal insufficiency in 170. Gonyea JE, Anderson CF: Weight change and serum people with type 1 diabetes. Diabetes Care 22:743-751, lipoproteins in recipients of renal allografts. Mayo Clin Proc 154. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving H-H: Progression of diabetic nephropathy. Kidney Int 59:702- 171. Brown JH, Murphy BG, Douglas AF, et al: Influence of immunosuppressive therapy on lipoprotein(a) and other 155. Massy ZA, Khoa TN, Lacour B, Descamps-Latscha lipoproteins following renal transplantation. Nephron 75:277- B, Man NK, Jungers P: Dyslipidaemia and the progression of renal disease in chronic renal failure patients. Nephrol 172. Moore R, Thomas D, Morgan E, et al: Abnormal lipid and lipoprotein profiles following renal transplantation.
156. Samuelsson O, Attman PO, Knight-Gibson C, et al: Plasma levels of lipoprotein (a) do not reflect progression of 173. Querfeld U, LeBoeuf RC, Salusky IB, Nelson P, human chronic renal failure. Nephrol Dial Transplant 11: Laidlaw S, Fine RN: Lipoproteins in children treated with continuous peritoneal dialysis. Pediatr Res 29:155-159, 1991 157. Yokoyama H, Tomonaga O, Hirayama M, et al: 174. Querfeld U, Lang M, Friedrich JB, Kohl B, Fiehn Predictors of the progression of diabetic nephropathy and W, Scharer K: Lipoprotein(a) serum levels and apolipopro- the beneficial effect of angiotensin-converting enzyme inhibi- tein(a) phenotypes in children with chronic renal disease.
tors in NIDDM patients. Diabetologia 40:405-411, 1997 158. Samuelsson O, Mulec H, Knight-Gibson C, et al: 175. Scolnik D, Balfe JW: Initial hypoalbuminemia and Lipoprotein abnormalities are associated with increased rate hyperlipidemia persist during chronic peritoneal dialysis in of progression of human chronic renal insufficiency. Neph- children. Perit Dial Int 13:136-139, 1993 176. Querfeld U, Salusky IB, Nelson P, Foley J, Fine RN: 159. Nielsen S, Schmitz A, Rehling M, Mogensen CE: Hyperlipidemia in pediatric patients undergoing peritoneal The clinical course of renal function in NIDDM patients dialysis. Pediatr Nephrol 2:447-452, 1988 with normo- and microalbuminuria. J Intern Med 241:133- 177. Broyer M, Niaudet P, Champion G, Jean G, Chopin N, Czernichow P: Nutritional and metabolic studies in children on continuous ambulatory peritoneal dialysis. Kid- cholesterol (LDL-C) in hemodialysis patients. Clin Biochem 178. Bakkaloglu SA, Ekim M, Tumer N, Soylu K: The 194. Sentı´ M, Pedro-Botet J, Nogue¨s X, Rubie¨s-Prat J: effect of CAPD on the lipid profile of pediatric patients. Perit Influence of intermediate-density lipoproteins on the accu- racy of the Friedewald formula. Clin Chem 37:1394-1397, 179. Silverstein DM, Palmer J, Polinsky MS, Braas C, Conley SB, Baluarte HJ: Risk factors for hyperlipidemia in 195. Ticho BS, Neufeld EJ, Newburger JW, Harris N, long-term pediatric renal transplant recipients. Pediatr Neph- Baker A, Rifai N: Utility of direct measurement of low- density lipoprotein cholesterol in dyslipidemic pediatric 180. Goldstein S, Duhamel G, Laudat MH, et al: Plasma patients. Arch Pediatr Adolesc Med 152:787-791, 1998 lipids, lipoproteins and apolipoproteins AI, AII, and B in 196. Gore JM, Goldberg RJ, Matsumoto AS, Castelli WP, renal transplanted children: What risk for accelerated athero- McNamara PM, Dalen JE: Validity of serum total choles- terol level obtained within 24 hours of acute myocardial 181. Van Gool S, Van Damme-Lombaerts R, Cobbaert C, infarction. Am J Cardiol 54:722-725, 1984 Proesmans W, Eggermont E: Lipid and lipoprotein abnormali- 197. Ryder REJ, Hayes TM, Mulligan IP, Kingswood JC, ties in children on hemodialysis and after renal transplanta- Willimas S, Owens DR: How soon after myocardial infarc- tion should plasma lipid values be assessed? BMJ 289:1651- 182. Milliner DS, Morgenstern BZ, Murphy M, Gonyea J, Sterioff S: Lipid levels following renal transplantation in 198. Henkin Y, Crystal E, Goldberg Y, et al: Usefulness pediatric recipients. Transplant Proc 26:112-114, 1994 of lipoprotein changes during acute coronary syndromes for 183. Singh A, Tejani C, Benfield M, Tejani A: Sequential predicting postdischarge lipoprotein levels. Am J Cardiol analysis of the lipid profile of children post-renal transplan- tation. Pediatr Transplant 2:216-223, 1998 199. Mendez I, Hachinski V, Wolfe B: Serum lipids after 184. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemi- 200. Gallin JI, Kaye D, O’Leary WM: Serum lipids in ology of cardiovascular disease in chronic renal disease.
infection. N Engl J Med 281:1081-1086, 1969 Am J Kidney Dis 32:S112-S119, 1998 (suppl 3) 201. Alvarez C, Ramos A: Lipids, lipoproteins, and apo- 185. Parekh RS, Carroll CE, Wolfe RA, Port FK: Cardio- proteins in serum during infection. Clin Chem 32:142-145, vascular mortality in children and young adults with end- stage kidney disease. J Pediatr 141:191-197, 2002 202. Sammalkorpi K, Valtonen V, Kerttula Y, Nikkila¨ E, 186. Strong JP, Malcom GT, McMahan CA, et al: Preva- Taskinen M-R: Changes in serum lipoprotein pattern in- lence and extent of atherosclerosis in adolescents and young duced by acute infections. Metabolism 37:859-865, 1988 adults: implications for prevention from the Pathobiological 203. Figueroa O, Franco-Saenz R, Mulrow PJ, Mon- Determinants of Atherosclerosis in Youth Study. JAMA tesinos E: Changes in cholesterol levels after coronary artery bypass surgery. Am J Med Sci 303:73-77, 1992 187. Antikainen M, Sariola H, Rapola J, Taskinen M-R, 204. Aufenanger J, Walter H, Kattermann R: [Studies of Holtho¨fer H, Holmberg C: Pathology of renal arteries of lipid and lipoprotein metabolism in man after surgical inter- dyslipidemic children with congenital nephrosis. APMIS ventions]. Langenbecks Arch Chir 378:41-48, 1993 205. Akgun S, Ertel NH, Mosenthal A, Oser W: Postsur- 188. Nayir A, Bilge I, Kilicaslan I, Ander H, Emre S, gical reduction of serum lipoproteins: Interleukin-6 and the Sirin A: Arterial changes in paediatric haemodialysis pa- acute-phase response. J Lab Clin Med 131:103-108, 1998 tients undergoing renal transplantation. Nephrol Dial Trans- 206. Dominguez-Munoz JE, Malfertheiner P, Ditschuneit HH, et al: Hyperlipidemia in acute pancreatitis. Relationship 189. Olson RE: Atherogenesis in children: Implications with etiology, onset, and severity of the disease. Int J for the prevention of atherosclerosis. Adv Pediatr 47:55-78, 207. Glueck CJ, Lang J, Hamer T, Tracy T: Severe 190. National Heart, Lung and Blood Institute: The Lipid hypertriglyceridemia and pancreatitis when estrogen replace- Research Clinics Population Studies Data Book: Volume ment therapy is given to hypertriglyceridemic women. J Lab 1—The Prevalence Study. Bethesda, MD, US Department of Health and Human Services, Public Health Service, National 208. Kasiske BL, Heim-Duthoy KL: Transient reductions Institute of Health, NIH Pub. No. 80-1527, July 1980 in serum cholesterol after renal transplantation. Am J Kid- 191. Friedewald WT, Levy RI, Fredrickson DS: Estima- tion of the concentration of low-density lipoprotein choles- 209. Kasiske BL, Vazquez MA, Harmon WE, et al: terol in plasma, without use of the preparative ultracentri- Recommendations for the outpatient surveillance of renal transplant recipients. J Am Soc Nephrol 11:S1, 2000 192. Nauck M, Kramer-Guth A, Bartens W, Marz W, 210. Johnson C, Ahsan N, Gonwa T, et al: Randomized Wieland H, Wanner C: Is the determination of LDL choles- trial of tacrolimus (Prograf) in combination with azathio- terol according to Friedewald accurate in CAPD and HD prine or mycophenolate mofetil versus cyclosporine (Ne- oral) with mycophenolate mofetil after cadaveric kidney 193. Bairaktari E, Elisaf M, Tzallas C, et al: Evaluation transplantation. Transplantation 69:834-841, 2000 of five methods for determining low-density lipoprotein 211. McCune TR, Thacker LRII, Peters TG, et al: Effects of tacrolimus on hyperlipidemia after successful renal trans- National Health and Nutrition Examination Survey. Athero- plantation: A Southeastern Organ Procurement Foundation multicenter clinical study. Transplantation 65:87-92, 1998 227. Verges BL: Dyslipidaemia in diabetes mellitus. Re- 212. Vanrenterghem Y, Lebranchu Y, Hene´, R, Oppenhei- view of the main lipoprotein abnormalities and their conse- mer F, Ekberg, H: Double-blind comparison of two cortico- quences on the development of atherogenesis. Diabet Metab steroid regimens plus mycophenolate mofetil and cyclspo- rine for prevention of acute renal allograft rejection.
228. Best JD, O’Neal DN: Diabetic dyslipidaemia: Cur- rent treatment recommendations. Drugs 59:1101-1111, 2000 213. Curtis JJ, Galla JH, Woodford SY, Lucas BA, Luke 229. Betteridge DJ: Diabetic dyslipidaemia. Diabet Obes RG: Effect of alternate-day prednisone on plasma lipids in renal transplant recipients. Kidney Int 22:42-47, 1982 230. Avogaro P, Cazzolato G: Changes in the composi- 214. Hollander AA, Hene RJ, Hermans J, Van Es LA, van tion and physico-chemical characteristics of serum lipopro- der Woude FJ: Late prednisone withdrawal in cyclosporine- teins during ethanol-induced lipaemia in alcoholic subjects.
treated kidney transplant patients: A randomized study. J Am 231. Castelli WP, Doyle JT, Gordon T, et al: Alcohol and 215. Hilbrands LB, Demacker PN, Hoitsma AJ, Stalen- blood lipids. The cooperative lipoprotein phenotyping study.
hoef AF, Koene RA: The effects of cyclosporine and pred- nisone on serum lipid and (apo)lipoprotein levels in renal 232. Lifton L, Scheig R: Ethanol-induced hypertriglycer- transplant recipients. J Am Soc Nephrol 5:2073-2081, 1995 idemia. Prevalence and contributing factors. Am J Clin Nutr 216. John GT, Dakshinamurthy DS, Jeyaseelan L, Jacob CK: The effect of cyclosporin A on plasma lipids during the 233. Marth E, Cazzolato G, Bittolo BG, Avogaro P, first year after renal transplantation. Natl Med J India 12:14- Kostner GM: Serum concentrations of Lp(a) and other lipoprotein parameters in heavy alcohol consumers. AnnNutr Metab 26:56-62, 1982 217. Ingram AJ, Parbtani A, Churchill DN: Effects of two 234. Taskinen MR, Nikkila EA, Valimaki M, et al: Alco- low-flux cellulose acetate dialysers on plasma lipids and hol-induced changes in serum lipoproteins and in their lipoproteins—A cross-over trial. Nephrol Dial Transplant 235. Seidel D: Hyperlipoproteinemias and liver disease.
218. Joven J, Villabona C, Vilella E, Masana L, Albertı´ R, Valle¨s M: Abnormalities of lipoprotein metabolism in pa- 236. Muller P, Felin R, Lambrecht J, et al: Hypertriglyc- tients with the nephrotic syndrome. N Engl J Med 323:579- eridaemia secondary to liver disease. Eur J Clin Invest 219. Joven J, Espinel E, Simo JM, Vilella E, Camps J, 237. Iglesias A, Arranz M, Alvarez JJ, et al: Cholesteryl Oliver A: The influence of hypoalbuminemia in the genera- ester transfer activity in liver disease and cholestasis, and its tion of nephrotic hyperlipidemia. Atherosclerosis 126:243- relation with fatty acid composition of lipoprotein lipids.
220. Kaysen GA, Don B, Schambelan M: Proteinuria, 238. Flynn WJ, Freeman PG, Wickboldt LG: Pancreatitis albumin synthesis and hyperlipidaemia in the nephrotic associated with isotretinoin-induced hypertriglyceridemia.
syndrome. Nephrol Dial Transplant 6:141-149, 1991 221. Warwick GL, Packard CJ, Demant T, Bedford DK, 239. Tangrea JA, Adrianza E, Helsel WE, et al: Clinical Boulton-Jones JM, Shepherd J: Metabolism of apolipopro- and laboratory adverse effects associated with long-term, tein B-containing lipoproteins in subjects with nephrotic- low-dose isotretinoin: Incidence and risk factors. The Isotreti- range proteinuria. Kidney Int 40:129-138, 1991 noin-Basal Cell Carcinomas Study Group. Cancer Epide- 222. Stenvinkel P, Berglund L, Ericsson S, Alvestrand A, Angelin B, Eriksson M: Low-density lipoprotein metabo- 240. Koistinen HA, Remitz A, Gylling H, Miettinen TA, lism and its association to plasma lipoprotein(a) in the Koivisto VA, Ebeling P: Dyslipidemia and a reversible nephrotic syndrome. Eur J Clin Invest 27:169-177, 1997 decrease in insulin sensitivity induced by therapy with 223. Demant T, Mathes C, Gu¨tlich K, et al: A simulta- 13-cis-retinoic acid. Diabetes Metabol Res Rev 17:391-395, neous study of the metabolism of apolipoprotein B and albumin in nephrotic patients. Kidney Int 54:2064-2080, 241. Luoma PV, Myllyla VV, Sotaniemi EA, Hokkanen TE: Plasma HDL cholesterol in epileptics with elevated 224. O’Brien T, Dinneen SF, O’Brien PC, Palumbo PJ: triglyceride and cholesterol. Acta Neurol Scand 60:56-63, Hyperlipidemia in patients with primary and secondary hypothyroidism. Mayo Clin Proc 68:860-866, 1993 242. Verrotti A, Domizio S, Angelozzi B, Sabatino G, 225. Tsimihodimos V, Bairaktari E, Tzallas C, Miltiadus Morgese G, Chiarelli F: Changes in serum lipids and lipopro- G, Liberopoulos E, Elisaf M: The incidence of thyroid teins in epileptic children treated with anticonvulsants. J function abnormalities in patients attending an outpatient 243. Papacostas S: Oxcarbazepine versus carbamazepine 226. Morris MS, Bostom AG, Jacques PF, Selhub J, treatment and induction of serum lipid abnormalities. J Child Rosenberg IH: Hyperhomocysteinemia and hypercholester- olemia associated with hypothyroidism in the third US 244. Dube MP, Sprecher D, Henry WK, et al: Preliminary guidelines for the evaluation and management of dyslipide- sporine. Sirolimus European Renal Transplant Study Group.
mia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of 259. Hoogeveen RC, Ballantyne CM, Pownall HJ, et al: the Adult AIDS Clinical Trial Group Cardiovascular Disease Effect of sirolimus on the metabolism of ApoB100-contain- Focus Group. Clin Infect Dis 31:1216-1224, 2000 ing lipoproteins in renal transplant patients. Transplantation 245. Vergis EN, Paterson DL, Wagener MM, Swindells S, Singh N: Dyslipidaemia in HIV-infected patients: Associa- 260. Vierhapper H, Nardi A, Grosser P, Raber W, Gessl tion with adherence to potent antiretroviral therapy. Int J A: Low-density lipoprotein cholesterol in subclinical hypo- 246. Rakotoambinina B, Medioni J, Rabian C, Jubault V, 261. Laszlo A, Simon M: Serum lipid and lipoprotien Jais JP, Viard JP: Lipodystrophic syndromes and hyperlipid- levels in premature ageing syndrome: Total lipodystrophy emia in a cohort of HIV-1-infected patients receiving triple and Cockayne syndrome. Arch Gerontol Geriatr 5:189-196, combination antiretroviral therapy with a protease inhibitor.
J Acquir Immune Defic Syndr 27:443-449, 2001 262. Huemer C, Kitson H, Malleson PN, et al: Lipodys- 247. Kasiske BL, Ma JZ, Kalil RSN, Louis TA: Effects of trophy in patients with juvenile dermatomyositis—Evalua- antihypertensive agents on serum lipids. Ann Intern Med tion of clinical and metabolic abnormalities. J Rheumatol 248. Webb OL, Laskarzewski PM, Glueck CJ: Severe 263. Evliyaoglu O, Berberoglu M, Ocal G, Adiyaman P, depression of high-density lipoprotein cholesterol levels in Aycan Z: Severe hypercalcemia of an infant due to vitamin weight lifters and body builders by self-administered exog- D toxicity associated with hypercholesterolemia. J Pediatr enous testosterone and anabolic-androgenic steroids. Metabol 264. Jordan SC: Cardiac lesions in children with “hyper- 249. Thompson PD, Cullinane EM, Sady SP, et al: Con- calcaemic” facies. Bristol Med Chir J 84:121-123, 1969 trasting effects of testosterone and stanozolol on serum 265. Levy E, Thibault L, Roy CC, Letarte J, Lambert M, lipoprotein levels. JAMA 261:1165-1168, 1989 Seidman EG: Mechanisms of hypercholesterolaemia in gly- 250. Teruel JL, Lasuncion MA, Rivera M, et al: Nan- cogen storage disease type I: Defective metabolism of low drolone decanoate reduces serum lipoprotein(a) concentra- density lipoprotein in cultured skin fibroblasts. Eur J Clin tions in hemodialysis patients. Am J Kidney Dis 29:569-575, 266. Levy E, Thibault LA, Roy CC, Bendayan M, Lep- 251. Castelo-Branco C, Vicente JJ, Figueras F, et al: age G, Letar J: Circulating lipids and lipoproteins in glyco- Comparative effects of estrogens plus androgens and tibo- gen storage disease type I with nocturnal intragastric feed- lone on bone, lipid pattern and sexuality in postmenopausal 267. Forget PP, Fernandes J, Begemann PH: Triglyceride 252. van Stiphout WA, Grobbee DE, Hofman A, de clearing in glycogen storage disease. Pediatr Res 8:114-119, Bruijn AM: Do oral contraceptives increase blood pressure and serum total cholesterol in young women? Prev Med 268. Fernandes J, Pikaar NA: Hyperlipidemia in children with liver glycogen disease. Am J Clin Nutr 22:617-627, 253. Flint PM, Lapane KL, Barbour MM, Derby CA, Carleton RA, Hume AL: Cardiovascular risk profiles of oral contraceptive users and nonusers: A population-based study.
269. Tazawa Y, Yamada M, Nakagawa M, Konno T, Tada K: Biliary lipid compositions in cholestatic diseases of 254. Connelly PW, Stachenko S, MacLean DR, Petraso- vits A, Little JA: The prevalence of hyperlipidemia in 270. Robberecht E, Koletzko B, Christophe A: Several women and its association with use of oral contraceptives, mechanisms contribute to the abnormal fatty acid composi- sex hormone replacement therapy and nonlipid coronary tion of serum phospholipids and cholesterol esters in choles- artery disease risk factors. Canadian Heart Health Surveys tatic children with extrahepatic biliary atresia. Prostaglan- Research Group. Can J Cardiol 15:419-427, 1999 dins Leukot Essent Fatty Acids 56:199-204, 1997 255. Kupin W, Venkat KK, Oh HK, Dienst S: Complete 271. Mordasini R, Klose G, Greten H: Secondary type II replacement of methylprednisolone by azathioprine in cyclo- hyperlipoproteinemia in patients with anorexia nervosa. Me- sporine-treated primary cadaveric renal transplant recipi- 272. Halmi K, Fry M: Serum lipids in anorexia nervosa.
256. Ingulli E, Tejani A, Markell M: The beneficial ef- fects of steroid withdrawal on blood pressure and lipid 273. Szamosi T, Szollar J, Meggyesi V, Wilhelm O, profile in children posttransplantation in the cyclosporine Bodanszky H, Matyus J: Serum cholesterol and triglyceride levels in progeria: a model of ageing. Mech Ageing Dev 257. Hricik DE, Mayes JT, Schulak JA: Independent effects of cyclosporine and prednisone on posttransplant 274. Macnamara BG, Farn KT, Mitra AK, Lloyd JK, hypercholesterolemia. Am J Kidney Dis 18:353-358, 1991 Fosbrooke A: Progeria. Case report with long-term studies 258. Groth CG, Backman L, Morales JM, et al: Sirolimus of serum lipids. Arch Dis Child 45:553-560, 1970 (rapamycin)-based therapy in human renal transplantation: 275. Petri M, Spence D, Bone LR, Hochberg MC: Coro- Similar efficacy and different toxicity compared with cyclo- nary artery disease risk factors in the Johns Hopkins Lupus Cohort: Prevalence, recognition by patients, and preventive Therapeutic benefits of exercise training for hemodialysis patients. Kidney Int Suppl 16:S303-S309, 1983 276. Sondheimer HM, Lorts A: Cardiac involvement in 292. Soroka N, Silverberg DS, Greemland M, et al: inflammatory disease: Systemic lupus erythematosus, rheu- Comparison of a vegetable-based (soya) and an animal- matic fever, and Kawasaki disease. Adolesc Med 12:69-78, based low-protein diet in predialysis chronic renal failure 277. Rutsky EA, Robards M, Van Dyke JA, Rostand SG: 293. Khajehdehi P: Effect of vitamins on the lipid profile Acute pancreatitis in patients with end-stage renal disease of patients on regular hemodialysis. Scand J Urol Nephrol without transplantation. Arch Intern Med 146:1741-1745, 294. Khajehdehi P: Lipid-lowering effect of polyunsatu- 278. Padilla B, Pollak VE, Pesce A, Kant KS, Gilinsky rated fatty acids in hemodialysis patients. J Ren Nutr 10:191- NH, Deddens JA: Pancreatitis in patients with end-stage 295. Seri S, D’Alessandro A, Acitelli S, Giammaria U, 279. Keilani T, Schlueter WA, Levin ML, Batlle DC: Cocchi M, Noble RC: Effect of dietary supplementation by Improvement of lipid abnormalities associated with protein- alternative oils on blood lipid levels of haemodialysed uria using fosinopril, an angiotensin-converting enzyme inhibitor. Ann Intern Med 118:246-254, 1993 296. Schrader J, Stibbe W, Armstrong VW, et al: Compari- 280. Ravid M, Neumann L, Lishner M: Plasma lipids and son of low molecular weight heparin to standard heparin in the progression of nephropathy in diabetes mellitus type II: hemodialysis/hemofiltration. Kidney Int 33:890-896, 1988 Effect of ACE inhibitors. Kidney Int 47:907-910, 1995 297. Kronenberg F, Konig P, Lhotta K, Steinmetz A, 281. Schnack C, Hoffmann W, Hopmeier P, Schernthaner Dieplinger H: Low molecular weight heparin does not G: Renal and metabolic effects of 1-year treatment with necessarily reduce lipids and lipoproteins in hemodialysis ramipril or atenolol in NIDDM patients with microalbumin- 298. Saltissi D, Morgan C, Westhuyzen J, Healy H: 282. Agardh CD, Garcia-Puig J, Charbonnel B, An- Comparison of low-molecular-weight heparin (enoxaparin gelkort B, Barnett AH: Greater reduction of urinary albumin sodium) and standard unfractionated heparin for haemodialy- excretion in hypertensive type II diabetic patients with sis anticoagulation. Nephrol Dial Transplant 14:2698-2703, incipient nephropathy by lisinopril than by nifedipine. J 299. Blankestijn PJ, Vos PF, Rabelink TJ, van Rijn HJ, 283. Coggins CH, Dwyer JT, Greene T, Petot G, Snetse- Jansen H, Koomans HA: High-flux dialysis membranes laar LG, Van Lente F: Serum lipid changes associated with improve lipid profile in chronic hemodialysis patients. J Am modified protein diets: results from the feasibility phase of the Modification of Diet in Renal Disease Study. Am J 300. Golper TA, Wolfson M, Ahmad S, et al: Multicenter trial of L-carnitine in maintenance hemodialysis patients. I.
284. Yu-Poth S, Zhao G, Etherton T, Naglak M, Jonnal- Carnitine concentrations and lipid effects. Kidney Int 38:904- agadda S, Kris-Etherton PM: Effects of the National Choles- terol Education Program’s Step I and Step II dietary interven- 301. Weschler A, Aviram M, Levin M, Better OS, Brook tion programs on cardiovascular disease risk factors: A JG: High dose of L-carnitine increases platelet aggregation meta-analysis. Am J Clin Nutr 69:632-646, 1999 and plasma triglyceride levels in uremic patients on hemodi- 285. National Kidney Foundation Kidney Disease Out- comes Quality Initiative (K/DOQI) Clinical Practice Guide- 302. Nilsson-Ehle P, Cederblad G, Fagher B, Monti M, lines for Nutrition in Chronic Renal Failure. Am J Kidney Thysell H: Plasma lipoproteins, liver function and glucose metabolism in haemodialysis patients: Lack of effect of 286. Physical activity and cardiovascular health. NIH L-carnitine supplementation. Scand J Clin Lab Invest 45:179- Consensus Development Panel on Physical Activity and Cardiovascular Health. JAMA 276:241-246, 1996 303. Giorcelli G, Vacha G, Icardi GP: Drug treatment of 287. Castaneda C, Grossi L, Dwyer J: Potential benefits hypertriglyceridaemia in chronic uraemic patients: Prelimi- of resistance exercise training on nutritional status in renal nary report on D,L-carnitine and thiadenol. Proc Eur Dial 288. Wenger NK: Lipid metabolism, physical activity, 304. Casciani CU, Caruso U, Cravotto E, et al: L- and postmenopausal hormone therapy. Am J Kidney Dis carnitine in haemodialysed patients. Changes in lipid pat- 289. Halbert JA, Silagy CA, Finucane P, Withers RT, 305. Saltissi D, Morgan C, Rigby RJ, Westhuyzen J: Hamdorf PA: Exercise training and blood lipids in hyperlip- Safety and efficacy of simvastatin in hypercholesterolemic idemic and normolipidemic adults: A meta-analysis of ran- patients undergoing chronic renal dialysis. Am J Kidney Dis domized, controlled trials. Eur J Clin Nutr 53:514-522, 1999 290. Deligiannis A, Kouidi E, Tassoulas E, Gigis P, 306. Chang JW, Yang WS, Min WK, Lee SK, Park JS, Tourkantonis A, Coats A: Cardiac effects of exercise rehabili- Kim SB: Effects of simvastatin on high-sensitivity C- tation in hemodialysis patients. Int J Cardiol 70:253-266, reactive protein and serum albumin in hemodialysis patients.
291. Goldberg AP, Geltman EM, Hagberg JM, et al: 307. Chertow GM, Burke SK, Lazarus JM, et al: Poly[allylamine hydrochloride] (RenaGel): A noncalcemic 323. Renders L, Mayer-Kadner I, Koch C, et al: Efficacy phosphate binder for the treatment of hyperphosphatemia in and drug interactions of the new HMG-CoA reductase chronic renal failure. Am J Kidney Dis 29:66-71, 1997 inhibitors cerivastatin and atorvastatin in CsA-treated renal 308. Braunlin W, Zhorov E, Guo A, et al: Bile acid transplant recipients. Nephrol Dial Transplant 16:141-146, binding to sevelamer HCl. Kidney Int 62:611-619, 2002 309. Park JS, Jung HH, Yang WS, Kim SB, Min WK, Chi 324. Santos AF, Keitel E, Bittar AE, et al: Safety and HS: Effects of hormonal replacement therapy on lipid and efficacy of simvastatin for hyperlipidemia in renal transplant haemostatic factors in post-menopausal ESRD patients.
recipients: A double-blind, randomized, placebo-controlled Nephrol Dial Transplant 15:1835-1840, 2000 study. Transplant Proc 33:1194-1195, 2001 310. Harris KPG, Wheeler DC, Chong CC, and the Ator- 325. Pasternak RC, Smith SCJr, Bairey-Merz CN, Grundy vastatin in CAPD Study Investigators: A placebo-controlled SM, Cleeman JI, Lenfant C: ACC/AHA/NHLBI Clinical trial examining atorvastatin in dyslipidemic patients under- Advisory on the Use and Safety of Statins. Stroke 33:2337- going CAPD. Kidney Int 61:1469-1474, 2002 311. Bennett WM, Carpenter CB, Shapiro ME, et al: 326. Stern RH, Yang BB, Horton M, Moore S, Abel RB, Delayed omega-3 fatty acid supplements in renal transplan- Olson SC: Renal dysfunction does not alter the pharmacoki- tation. A double-blind, placebo-controlled study. Transplan- netics or LDL-cholesterol reduction of atorvastatin. J Clin 312. Urakaze M, Hamazaki T, Yano S, Kashiwabara H, 327. Halstenson CE, Triscari J, DeVault A, Shapiro B, Oomori K, Yokoyama T: Effect of fish oil concentrate on Keane W, Pan H: Single-dose pharmacokinetics of pravasta- risk factors of cardiovascular complications in renal trans- tin and metabolites in patients with renal impariment. J Clin plantation. Transplant Proc 21:2134-2136, 1989 313. Maachi K, Berthoux P, Burgard G, Alamartine E, 328. Gehr TWB, Sica DA, Slugg PH, Hammett JL, Berthoux F: Results of a 1-year randomized controlled trial Raymond R, Ford NF: The pharmacokinetics of pravastatin with omega-3 fatty acid fish oil in renal transplantation in patients on chronic hemodialysis. Eur J Clin Pharmacol under triple immunosuppressive therapy. Transplant Proc 329. Que´rin S, Lambert R, Cusson JR, et al: Single-dose 314. Holdaas H, Jardine AG, Wheeler DC, et al: Effect of pharmacokinetics of 14C-lovastatin in chronic renal failure.
fluvastatin on acute renal allograft rejection: A randomized multicenter trial. Kidney Int 60:1990-1997, 2001 330. Mazzu AL, Lettieri JT, Kelly E, et al: Influence of 315. Kasiske BL, Heim-Duthoy KL, Singer GG, Watsch- renal function on the pharmacokinetics of cerivastatin in inger B, Germain MJ, Bastani B: The effects of lipid- normocholesterolemic adults. Eur J Clin Pharmacol 56:69- lowering agents on acute renal allograft rejection. Transplan- 331. Lesne M, Sturbois X, Mercier M: Etude pharmaco- 316. Arnadottir M, Eriksson L-O, Germershausen JI, cinetique comparative de deux formes galeniques d’acide Thysell H, Eriksson LO: Low-dose simvastatin is a well- nicitinique. Pharmaceutica Acta Helvetica 51:367-370, 1976 tolerated and efficacious cholesterol-lowering agent in ciclo- 332. Abshagen U, Ko¨sters W, Kaufman B, Lang PD: sporin-treated kidney transplant recipients: Double-blind, Pharmacokinetics of bezafibrate after single and multiple randomized, placebo-controlled study in 40 patients. Nephron doses in the presence of renal failure. Klin Wochenschr 317. Martinez Hernandez BE, Persaud JW, Varghese Z, 333. Anderson P, Norbeck HE: Clinical pharmacokinet- Moorhead JF: Low-dose simvastatin is safe in hyperlipidae- ics of bezafibrate in patients with impaired renal function.
mic renal transplant patients. Nephrol Dial Transplant 8:637- 334. Williams AJ, Baker F, Walls J: The short term 318. Castro R, Queiro`s J, Fonseca I, et al: Therapy of effects of bezafibrate on the hypertriglyceridaemia of moder- post-renal transplantation hyperlipidaemia: Comparative ate to severe uraemia. Br J Clin Pharmacol 18:361-367, study with simvastatin and fish oil. Nephrol Dial Transplant 335. Goldberg AP, Sherrard DJ, Haas LB, Brunzell JD: 319. Katznelson S, Wilkinson AH, Kobashigawa JA, et Control of clofibrate toxicity in uremic hypertriglyceride- al: The effect of pravastatin on acute rejection after kidney mia. Clin Pharmacol Ther 21:317-325, 1977 transplantation—A pilot study. Transplantation 61:1469- 336. Viikari J, Anttila M, Kasanen A: The use of clofi- brate in patients with renal insufficiency. Int J Clin Pharma- 320. Kliem V, Wanner C, Eisenhauer T, et al: Comparison of pravastatin and lovastatin in renal transplant patients 337. Merk W, Graben N, Hartmann H, Nikolaus C, receiving cyclosporine. Transplant Proc 28:3126-3128, 1996 Schlierf G, Schwandt PSerum levels of free non-protein 321. Sahu K, Sharma R, Gupta A, et al: Effect of lova- bound clofibrinic acid after single dosing to patients with statin, an HMG CoA reductase inhibitor, on acute renal impaired renal function of various degrees—A multicenter allograft rejection. Clinical Transplant 15:173-175, 2001 study. Int J Clin Pharmacol Ther Toxicol 25:59-62, 1987 322. Kasiske BL, Tortorice KL, Heim-Duthoy KL, Gory- 338. Desager JP, Costermans J, Verberckmoes R, Har- ance JM, Rao KV: Lovastatin treatment of hypercholesterol- vengt C: Effect of hemodialysis on plasma kinetics of emia in renal transplant recipients. Transplantation 49:95- fenofibrate in chronic renal failure. Nephron 31:51-54, 1982 339. Knauf H, Kolle EU, Mutschler E: Gemfibrozil ab- sorption and elimination in kidney and liver disease. Klin 357. Kantola T, Kivisto KT, Neuvonen PJ: Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin 340. Evans JR, Forland SC, Cutler RE: The effect of renal function on the pharmacokinetics of gemfibrozil. J Clin 358. Mazzu AL, Lasseter KC, Shamblen EC, Agarwal V, Lettieri J, Sundaresen P: Itraconazole alters the pharmacoki- 341. Ridker PM, Rifai N, Clearfield M, et al: Measure- netics of atorvastatin to a greater extent than either cerivasta- ment of C-reactive protein for the targeting of statin therapy tin or pravastatin. Clin Pharmacol Ther 68:391-400, 2000 in the primary prevention of acute coronary events. N Engl 359. Neuvonen PJ, Jalava KM: Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin 342. Albert MA, Danielson E, Rifai N, Ridker PM, PRINCE Investigators: Effect of statin therapy on C-reactive 360. Kivisto KT, Kantola T, Neuvonen PJ: Different protein levels: The pravastatin inflammation/CRP evaluation effects of itraconazole on the pharmacokinetics of fluva- (PRINCE): A randomized trial and cohort study. JAMA statin and lovastatin. Brit J Clin Pharmacol 46:49-53, 1998 361. Neuvonen PJ, Kantola T, Kivisto KT: Simvastatin 343. Gotto AM, Farmer JA: Pleitropic effects of statins: but not pravastatin is very susceptible to interaction with the Do they matter? Curr Opin Lipidol 12:391-394, 2001 CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 63:332- 344. Munford RS: Statins and the acute-phase response.
362. Kantola T, Backman JT, Niemi M, Kivisto KT, 345. Simpson RJ Jr: Placing PRINCE in perspective.
Neuvonen PJ: Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol 56:225- 346. Asberg A, Hartmann A, Fjeldsa E, Bergan S, Hold- aas H: Bilateral pharmacokinetic interaction between cyclo- 363. Azie NE, Brater DC, Becker PA, Jones DR, Hall sporine A and atorvastatin in renal transplant recipients.
SD: The interaction of diltiazem with lovastatin and prava- statin. Clin Pharmacol Ther 64:369-377, 1998 347. Mu¨ck W, Mai I, Fritsche L, et al: Increase in 364. Mousa O, Brater DC, Sunblad KJ, Hall SD: The cerivastatin systemic exposure after single and multiple interaction of diltiazem with simvastatin. Clin Pharmacol dosing in cyclosporine-treated kidney transplant recipients.
365. Ziviani L, Da Ros L, Squassante L, Milleri S, 348. Arnadottir M, Eriksson L-O, Thysell H, Karkas JD: Cugola M, Iavarone LE: The effects of lacidipine on the Plasma concentration profiles of simvastatin 3-hydroxy-3- steady/state plasma concentrations of simvastatin in healthy methyl- glutaryl-coenzyme A reductase inhibitory activity in subjects. Brit J Clin Pharmacol 51:147-152, 2001 kidney transplant recipients with and without ciclosporin.
366. Jacobson RH, Wang P, Glueck CJ: Myositis and rhabdomyolysis associated with concurrent use of simvasta- 349. Ichimaru N, Takahara S, Kokado Y, et al: Changes in tin and nefazodone. JAMA 277:296-297, 1997 lipid metabolism and effect of simvastatin in renal transplant 367. Alderman CP: Possible interaction between nefaz- recipients induced by cyclosporine or tacrolimus. Atheroscle- odone and pravastatin. Ann Pharmacother 33:871, 1999 368. Lilja JJ, Kivisto KT, Neuvonen PJ: Grapefruit juice 350. Velosa JA, La Belle P, Ronca PD, et al: Pharmacoki- increases serum concentrations of atorvastatin and has no netics of lovastatin in renal transplant patients on azathio- effect on pravastatin. Clin Pharmacol Ther 66:118-127, 1999 prine or cyclosporine. J Am Soc Nephrol 1:325, 1990 (abstr) 369. Kantola T, Kivisto KT, Neuvonen PJ: Grapefruit 351. Cooper GR, Myers GL, Smith SJ, Schlant RC: juice greatly increases serum concentrations of lovastatin Blood lipid measurements. Variations and practical utility.
and lovastatin acid. Clin Pharmacol Ther 63:397-402, 1998 370. Lilja JJ, Kivisto KT, Neuvonen PJ: Grapefruit juice- 352. Olbricht C, Wanner C, Eisenhauer T, et al: Accumu- simvastatin interaction: Effect on serum concentrations of lation of lovastatin, but not pravastatin, in the blood of simvastatin, simvastatin acid, and HMG-CoA reductase in- cyclosporine-treated kidney graft patients after multiple hibitors. Clin Pharmacol Ther 64:477-483, 1998 doses. Clin Pharmacol Ther 62:311-321, 1997 371. DiTusa L, Luzier AB: Potential interaction between 353. Goldberg R, Roth D: Evaluation of fluvastatin in the troglitazone and atorvastatin. J Clin Pharm Ther 25:279-282, treatment of hypercholesterolemia in renal transplant recipi- ents taking cyclosporine. Transplantation 62:1559-1564, 1996 372. Lin JC, Ito MK: A drug interaction between troglita- 354. Kovarik JM, Hartmann S, Hubert M, et al: Pharma- zone and simvastatin. Diabetes Care 22:2104-2106, 1999 cokinetic and pharmacodynamic assessments of HMG-CoA 373. Kyrklund C, Backman JT, Kivisto KT, Neuvonen reductase inhibitors when coadministered with everolimus.
M, Laitila J, Neuvonen PJ: Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Phar- 355. Siedlik PH, Olson SC, Yang BB, Stern RH: Erythro- mycin coadministration increases plasma atorvastatin con- 374. Nakai A, Nishikata M, Matsuyama K, Ichikawa M: centrations. J Clin Pharmacol l39:501-504, 1999 Drug interaction between simvastatin and cholestyramine in 356. Kantola T, Kivisto KT, Neuvonen PJ: Erythromycin vitro and in vivo. Bio Pharm Bull 19:1231-1233, 1996 and verapamil considerably increase serum simvastatin and 375. Wen X, Wang J-S, Backman JT, Kivsto¨ KT, Neu- simvastatin acid concentrations. Clin Pharmacol Ther 64:177- vonen PJ: Gemfibrozil is a potent inhibitor of human cyto- chrome P450 2C9. Drug Metab Dispos 29:1359-1361, 2001 376. Backman JT, Kyrklund C, Kivisto KT, Wang JS, blood-glucose control with sulphonylureas or insulin com- Neuvonen PJ: Plasma concentrations of active simvastatin pared with conventional treatment and risk of complications acid are increased by gemfibrozil. Clin Pharmacol Ther in patients with type 2 diabetes (UKPDS 33). Lancet 352:837- 377. Pan W-J, Gustavson LE, Achari R, et al: Lack of a 393. Lageder H: [Comparative double-blind investiga- clinicallly significant pharmacokinenic interaction between tion of bezafibrate and clofibrate in patients with primary fenofibrate and pravstatin in healthy volunteers. J Clin hyperlipoproteinaemia]. Wien Klin Wochenschr 92:95-101, 378. Kyrklund C, Backman JT, Kivisto¨ KT, Neuvonen 394. Dick TB, Marples J, Ledermann HM, Whittington J: M, Laitila J, Neuvonen PJ: Plasma concentrations of active Comparative study of once and 3-times daily regimens of lovastatin acid are markedly increased by gemfibrozil but bezafibrate in patients with primary hyperlipoproteinaemia.
not by bezafibrate. Clin Pharmacol Ther 69:340-345, 2001 379. Spence JD, Munoz CE, Hendricks L, Latchinian L, 395. Mertz DP, Lang PD, Vollmar J: Bezafibrate: Lack of Khouri HE: Pharmacokinetics of the combination of fluva- effect on creatinine excretion and muscular proteins. Res statin and gemfibrozil. Am J Cardiol 76:80A-83A, 1995 380. Hunninghake D, Insull W Jr, Toth P, Davidson D, 396. Olsson AG, Lang PD, Vollmar J: Effect of bezafi- Donovan JM, Burke SK: Coadministration of colesevelam brate during 4.5 years of treatment of hyperlipoproteinae- hydrochloride with atorvastatin lowers LDL cholesterol ad- ditively. Atherosclerosis 158:407-416, 2001 397. Barbir M, Hunt B, Kushwaha S, et al: Maxepa 381. Chertow GM, Burke SK, Raggi P: Sevelamer attenu- versus bezafibrate in hyperlipidemic cardiac transplant recipi- ates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252, 2002 398. Lipkin GW, Tomson CRV: Severe reversible renal 382. Keogh A, Day R, Critchley L, Duggin G, Baron D: fairlue with bezafibrate. Lancet 341:371, 1993 The effect of food and cholestyramine in the absorption of 399. Bruce R, Daniels A, Cundy T: Renal function changes cyclosporine in cardiac transplant recipients. Transplant Proc in diabetic nephropathy induced by bezafibrate. Nephron 383. Jensen RA, Lal SM, Diaz-Arias A, et al: Does 400. Hirai M, Tatuso E, Sakurai M, Ichikawa M, Matsuya cholestyramine interfere with cyclosporine absorption? A F, Saito Y: Elevated blood concentrations of cyclosporine prospective study in renal transplant patients. ASAIO J and kidney failure after bezafibrate in renal graft recipient.
Ann Pharmacother 30:883-884, 1996 (letter) 384. Austin MA, Hokanson JE, Edwards KL: Hypertri- 401. Broeders N, Knoop C, Antoine M, Tielemans C, glyceridemia as a cardiovascular risk factor. Am J Cardiol Abramowicz D: Fibrate-induced increase in blood urea and creatinine: Is gemfibrozil the only inonocuous agent? Neph- 385. Assmann G, Schulte H, Funke H, Von Eckardstein A: The emergence of triglycerides as a significant inde- 402. Devuyst O, Goffin E, Pirson Y, van Ypersele de pendent risk factor in coronary artery disease. Eur Heart J19: Strihou C: Creatinine rise after fibrate therapy in renal graft 386. Cui Y, Blumenthal RS, Flaws JA, et al: Non-high- 403. Ro¨ssner S, Oro¨ L: Fenofibrate therapy of hyperli- density lipoprotein cholesterol level as a predictor of cardio- poproteinaemia. A dose-response study and a comparison vascular disease mortality. Arch Intern Med 161:1413-1419, with clofibrate. Atherosclerosis 38:273-282, 1981 404. Rouffy J, Chanu B, Bakir R, Djian F, Goy-Loeper J: 387. Abate N, Vega GL, Grundy SM: Variability in Comparative evaluation of the effects of ciprofibrate and cholesterol content and physical properties of lipoproteins fenofibrate on lipids, lipoproteins and apoproteins A and B.
containing apolipoprotein B-100. Atherosclerosis 104:159- 405. deLorgeril M, Boissonnat P, Bizollon CA, et al: 388. Plasma lipid distributions in selected North Ameri- Pharmacokinetics of cyclosporine in hyperlipidaemic long- can populations: The Lipid Research Clinics Program Preva- term survivors of heart transplantation. Lack of interaction lence Study. The Lipid Research Clinics Program Epidemi- with the lipid-lowering agent, fenofibrate. Eur J Clin Pharma- ology Committee. Circulation 60:427-439, 1979 389. Shoji T, Nishizawa Y, Kawagishi T, et al: Athero- 406. Boissonnat P, Salen P, Guidollet J, et al: The long- genic lipoprotein changes in the absence of hyperlipidemia term effects of the lipid-lowering agent fenobibrate in hyper- in patients with chronic renal failure treated by hemodialy- lipidemic heart transplant recipients. Transplantation 58:245- 390. Effect of intensive diabetes management on macro- 407. Ellen RL, McPherson R: Long-term efficacy and vascular events and risk factors in the Diabetes Control and safety of fenofibrate and a statin in the treatment of com- Complications Trial. Am J Cardiol 75:894-903, 1995 bined hyperlipidemia. Am J Cardiol 81:60B-65B, 1998 391. Lawson ML, Gerstein HC, Tsui E, Zinman B: Effect 408. Hottelart C, el Esper N, Achard JM, Pruna A, of intensive therapy on early macrovascular disease in Fournier A: [Fenofibrate increases blood creatinine, but does young individuals with type 1 diabetes. A systematic review not change the glomerular filtration rate in patients with mild and meta-analysis. Diabetes Care 22:B35-B39, 1999 (suppl 2) renal insufficiency]. Nephrologie 20:41-44, 1999 392. UK Prospective Diabetes Study Group: Intensive 409. Dierkes J, Westphal S, Luley C: Serum homocys- teine increases after therapy with fenofibrate or bezafibrate.
fat intake in the prospective, randomized STRIP baby trial.
410. Lipscombe J, Lewis GF, Cattran D, Bargman JM: 427. Niinikoski H, Koskinen P, Punnonen K, et al: Intake Deterioration in renal function associated with fibrate therapy.
and indicators of iron and zinc status in children consuming diets low in saturated fat and cholesterol: The STRIP baby 411. Gibbons LW, Gonzalez V, Gordon N, Grundy S: The study. Special Turku Coronary Risk Factor Intervention prevalence of side effects with regular and sustained-release Project for Babies. Am J Clin Nutr 66:569-574, 1997 nicotinic acid. Am J Med 99:378-385, 1995 428. Niinikoski H, Lapinleimu H, Viikari J, et al: Growth 412. Morgan JM, Capuzzi DM, Guyton JR: A new ex- until 3 years of age in a prospective, randomized trial of a tended-release niacin (Niaspan): Efficacy, tolerability, and diet with reduced saturated fat and cholesterol. Pediatrics safety in hypercholesterolemic patients. Am J Cardiol 82: 429. Lambert M, Lupien PJ, Gagne C, et al: Treatment of 413. Gokal R, Mann JI, Oliver DO, Ledingham JGG, familial hypercholesterolemia in children and adolescents: Carter RD: Treatment of hyperlipidaemia in patients on Effect of lovastatin. Canadian Lovastatin in Children Study 414. Spratt P, Esmore D, Keogh A, Chang V: Comparison 430. Knipscheer HC, Boelen CC, Kastelein JJ, et al: of three immunosuppressive protocols in cardiac transplanta- Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res 39:867-871, 415. Chen HH, Lin LH: Recurrent pancreatitis secondary to type V hyperlipidemia: Report of one case. Acta Paediatr 431. Couture P, Brun LD, Szots F, et al: Association of specific LDL receptor gene mutations with differential plasma 416. Colletti RB, Neufeld EJ, Roff NK, McAuliffe TL, lipoprotein response to simvastatin in young French Canadi- Baker AL, Newburger JW: Niacin treatment of hypercholes- ans with heterozygous familial hypercholesterolemia. Arte- terolemia in children. Pediatrics 92:78-82, 1993 rioscler Thromb Vasc Biol 18:1007-1012, 1998 417. Steinmetz J, Morin C, Panek E, Siest G, Drouin P: 432. Vohl MC, Szots F, Lelie’vre M, et al: Influence of Biological variations in hyperlipidemic children and adoles- LDL receptor gene mutation and apo E polymorphism on cents treated with fenofibrate. Clin Chim Acta 112:43, 1981 lipoprotein response to simvastatin treatment among adoles- 418. Chicaud P, Demange J, Drouin P, Debry G: [Action cents with heterozygous familial hypercholesterolemia. Ath- of fenofibrate in hypercholesterolemic children. 18-month 433. Stefanutti C, Lucani G, Vivenzio A, Di Giacomo S: 419. Wheeler KA, West RJ, Lloyd JK, Barley J: Double Diet only and diet plus simvastatin in the treatment of blind trial of bezafibrate in familial hypercholesterolaemia.
heterozygous familial hypercholesterolemia in childhood.
420. Kwiterovich PO Jr: Diagnosis and management of 434. Coleman JE, Watson AR: Hyperlipidaemia, diet and familial dyslipoproteinemia in children and adolescents.
simvastatin therapy in steroid-resistant nephrotic syndrome of childhood. Pediatr Nephrol 10:171-174, 1996 421. Enos WF, Holmes RH, Beyer J: Coronary artery 435. Sanjad SA, al Abbad A, al Shorafa S: Management disease among United States soldiers killed in action in of hyperlipidemia in children with refractory nephrotic syn- drome: the effect of statin therapy. J Pediatr 130:470-474, 422. McGill HC Jr, McMahan CA, Herderick EE, et al: Effects of coronary heart disease risk factors on atherosclero- 436. Kano K, Hoshi E, Ito S, et al: Effects of combination sis of selected regions of the aorta and right coronary artery therapy consisting of moderate-dose intravenous immuno- PDAY Research Group. Pathobiological Determinants of globulin G, pulsed methylprednisolone and pravastatin in Atherosclerosis in Youth. Arterioscler Thromb Vasc Biol children with steroid-resistant nephrosis. Nephron 84:99- 423. Berenson GS, Srinivasan SR, Bao W, Newman 437. McCrindle BW, O’Neill MB, Cullen-Dean G, Hel- WPIII, Tracy RE, Wattigney WA: Association between mul- den E: Acceptability and compliance with two forms of tiple cardiovascular risk factors and atherosclerosis in chil- cholestyramine in the treatment of hypercholesterolemia in dren and young adults. The Bogalusa Heart Study. N Engl children: a randomized, crossover trial. J Pediatr 130:266- 424. Ja¨rvisalo MJ, Jartti L, Na¨nto¨-Salonen K, et al: In- 438. West RJ, Lloyd JK, Leonard JV: Long-term fol- creased aortic intima-media thickness: A marker of preclini- low-up of children with familial hypercholesterolaemia cal atherosclerosis in high-risk children. Circulation 104: treated with cholestyramine. Lancet 2:873-875, 1980 439. West RJ, Lloyd JK: The effect of cholestyramine on 425. Kwiterovich POJr, Barton BA, McMahon RP, et al: intestinal absorption. Gut 16:93-98, 1975 Effects of diet and sexual maturation on low-density lipopro- 440. Schwarz KB, Goldstein PD, Witztum JL, Schonfeld tein cholesterol during puberty: The Dietary Intervention G: Fat-soluble vitamin concentrations in hypercholester- Study in Children (DISC). Circulation 96:2526-2533, 1997 olemic children treated with colestipol. Pediatrics 65:243- 426. Niinikoski H, Viikari J, Ronnemaa T, et al: Regula- tion of growth of 7- to 36-month-old children by energy and 441. Schlierf G, Vogel G, Kohlmeier M, Vuilleumier JP, Huppe R, Schmidt-Gayk H: [Long-term therapy of familial 447. Bowes AdP (revised by Pennington JAT): Bowes & hypercholesterolemia in young patients with colestipol: avail- Church’s Food Values of Portions Commonly Used (ed 17).
ability of minerals and vitamins]. Klin Wochenschr 63:802- Philadelphia, PA, Lippincott, 1998, pp 1-481 448. Gylling H, Siimes MA, Miettinen TA: Sitostanol 442. Marcucci R, Zanazzi M, Bertoni E, et al: Risk ester margarine in dietary treatment of children with familial factors for cardiovascular disease in renal transplant recipi- hypercholesterolemia. J Lipid Res 36:1807-1812, 1995 ents: new insights. Transplant Int 13:S419-S424, 2000 449. Williams CL, Bollella MC, Strobino BA, Boccia L, Campanaro L: Plant stanol ester and bran fiber in childhood: 443. Stein EA, Illingworth DR, Kwiterovich PO Jr, et al: effects on lipids, stool weight and stool frequency in pre-school children. J Am Coll Nutr 18:572-581, 1999 Efficacy and safety of lovastatin in adolescent males with 450. Miettinen TA, Puska P, Gylling H, Vanhanen H, heterozygous familial hypercholesterolemia: a randomized Vartiainen E: Reduction of serum cholesterol with sitostanol- ester margarine in a mildly hypercholesterolemic popula- 444. Knipscheer HC, Boelen CC, Kastelein JJ, et al: Short-term efficacy and safety of pravastatin in 72 children 451. Weststrate JA, Meijer GW: Plant sterol-enriched with familial hypercholesterolemia. Pediatr Res 39:867-871, margarines and reduction of plasma total- and LDL- choles- terol concentrations in normocholesterolaemic and mildly 445. Canadian Task Force on the Periodic Health Exami- hypercholesterolaemic subjects. Eur J Clin Nutr 52:334-343, nation: Task Force Report on the Periodic Health Examina- tion. Can Med Assoc J 121:1193-1254, 1979 452. Hallikainen MA, Sarkkinen ES, Uusitupa MI: Plant 446. National Kidney Foundation: K/DOQI clinical prac- stanol esters affect serum cholesterol concentrations of hy- tice guidelines for nutrition in chronic renal failure. K/DOQI.
percholesterolemic men and women in a dose-dependent Am J Kidney Dis 35:S1-S140, 2000 (suppl 2)

Source: http://www.nefrologia.sochipe.cl/subidos/catalogo3/DISLIPIDEMIAS%20V.pdf

Srgoodfriday201

Who Was this Jesus? John 18:1 - 19:37 Good Friday, April 22, 2011 St. Alban’s, Hickory, NC Our Lenten journey, our Holy Week journey is almost over. This week juxtaposes the extremes of Jesus’ earthly ministry and the human reaction to it: waving of palms and welcome cries of Hosanna, followed by cries to crucify him and rejection and denial, contrasted with Jesus’ steadily, purposefully

Copyright © 2010-2014 Medical Articles